Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $161,000.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the sale, the insider now directly owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $14.85 on Thursday. The stock has a fifty day moving average price of $14.45 and a 200 day moving average price of $14.41. The stock has a market cap of $1.50 billion, a PE ratio of -14.42 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.30 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period last year, the firm earned ($0.54) EPS. As a group, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DAWN. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. JPMorgan Chase & Co. lowered their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Finally, Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.71.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC grew its position in shares of Day One Biopharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after purchasing an additional 1,447 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $3,230,000. Estuary Capital Management LP increased its position in Day One Biopharmaceuticals by 82.5% during the first quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares in the last quarter. Bayesian Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals in the first quarter worth $221,000. Finally, Janus Henderson Group PLC lifted its position in shares of Day One Biopharmaceuticals by 19.8% in the first quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after acquiring an additional 336,281 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.